医学部・先端ロボット・内視鏡手術学

Medicine and Dentistry

1. Abdominal Cancer 12%
2. Adenocarcinoma 18%
3. Adjuvant Chemotherapy 14%
4. Advanced Cancer 7%
5. Adverse Event 6%
6. Anal Fistula 11%
7. Appendectomy 11%
8. Biopsy 16%
9. Bleeding 34%
10. Cancer 11%
11. Cancer Surgery 35%
12. Carcinoma 12%
13. Chemoradiotherapy 27%
14. Chylothorax 11%
15. Cisplatin 6%
16. Clinical Feature 11%
17. Clinical Stage 8%
18. Cohort Analysis 12%
19. Colectomy 14%
20. Colon Cancer 14%
21. Colon Motility 11%
22. Colorectal Cancer 12%
23. Colorectal Carcinoma 11%
24. Conversion Therapy 11%
25. Crohn's Disease 11%
26. Da Vinci Surgical System 28%
27. Daikenchuto 11%
28. Debridement 5%
29. Disease 11%
30. Distal Pancreatectomy 11%
31. Empyema 11%
32. Endoscopic Surgery 11%
33. Endoscopic Ultrasound 7%
34. Esophageal Cancer 11%
35. Esophagectomy 11%
36. Esophagus 11%
37. First-Line Chemotherapy 5%
38. Fistula 16%
39. Fluorouracil 8%
40. FOLFIRI 11%
41. Gastrectomy 68%
42. Gastroesophageal Junction 11%
43. Gastrointestinal Stromal Tumor 38%
44. Granular Cell Tumor 11%
45. Hazard Ratio 13%
46. Hepatectomy 16%
47. Imatinib 22%
48. Incision 11%
49. Intestine Cancer 11%
50. Kocher Manoeuvre 11%
51. Laparoscopic Surgery 21%
52. Laparoscopy 37%
53. Leiomyosarcoma 11%
54. Lipiodol 5%
55. Liver Arteriography 11%
56. Liver Metastasis 22%
57. Local Excision 8%
58. Logistic Regression Analysis 7%
59. Lung Surgery 5%
60. Lymph Node 25%
61. Lymph Node Metastasis 33%
62. Lymphangiography 11%
63. Magnetic Resonance Imaging 7%
64. Malignant Neoplasm 18%
65. Metastatic Carcinoma 27%
66. Multimodality Cancer Therapy 11%
67. Neoadjuvant Therapy 14%
68. Neoplasm 91%
69. Operation Duration 7%
70. Pancreas Cancer 11%
71. Paraaortic Lymph Node 13%
72. Perianal Abscess 11%
73. Postoperative Complication 23%
74. Preoperative Chemotherapy 6%
75. Propensity Score Matching 14%
76. Prospective Study 13%
77. Radiation Therapy 17%
78. Rectum Cancer 100%
79. Rectum Resection 7%
80. Rectum Surgery 11%
81. Recurrent Disease 58%
82. Retroperitoneal Lymph Node Dissection 19%
83. Retrospective Study 33%
84. Robot-Assisted Surgery 37%
85. Sigmoid Cancer 14%
86. Squamous Cell Carcinoma 11%
87. Stenting 11%
88. Stomach Cancer 53%
89. Stomach Surgery 11%
90. Superior Mesenteric Artery 11%
91. Surgeon 23%
92. Surgery 42%
93. Surgical Anastomosis 6%
94. Surgical Margin 21%
95. Thorax Surgery 11%
96. Total Stomach Resection 5%
97. Tumor Recurrence 6%
98. Ulcerative Colitis 11%
99. Upper Gastrointestinal Surgery 11%
100. Venous Ulcer 5%

Keyphrases

1. Adjuvant Chemotherapy 16%
2. After Surgery 11%
3. Anal Squamous Cell Carcinoma 22%
4. Blood Loss 10%
5. Cancer-related 11%
6. Carcinoma Associated with Anal Fistula 11%
7. Chemoradiotherapy 11%
8. Chemotherapy 18%
9. Cisplatin Delivery 11%
10. Clinical Experience 11%
11. Clinical Features 11%
12. Colon Cancer Patients 11%
13. Colorectal Cancer 39%
14. Colorectal Cancer Patients 11%
15. Confidence Interval 9%
16. Conversion Surgery 11%
17. Conversion Therapy 11%
18. Crohn's Disease 11%
19. CT during Hepatic Arteriography 11%
20. Curative Resection 11%
21. Curative Surgery 16%
22. Da Vinci Surgical System 14%
23. Da Vinci Xi System 12%
24. Duodenal Gastrointestinal Stromal Tumors 11%
25. Endoscopic Surgical Skill Qualification System 11%
26. Esophageal Stenting 11%
27. Esophagorespiratory Fistula 11%
28. Expert Survey 11%
29. First-line Chemotherapy 5%
30. FOLFIRI 11%
31. FOLFIRINOX 11%
32. Gastric Bypass Surgery 11%
33. Gastric Cancer 22%
34. Gastric Cancer with Liver Metastasis 11%
35. Gastrointestinal Stromal Tumor 11%
36. Hazard Ratio 9%
37. High Risk 12%
38. Hinotori 11%
39. Histological Remission 11%
40. Intestinal Cancer 11%
41. Japan 9%
42. Japanese Population 11%
43. Kocher Maneuver 11%
44. Laparoscopy-assisted Gastrectomy 11%
45. Lateral Lymph Node Metastasis 11%
46. Leiomyosarcoma 11%
47. Leonardo Da Vinci 18%
48. Lipiodol Lymphangiography 7%
49. Liver Surface 7%
50. Local Gastrectomy 11%
51. Low Rectal Cancer 11%
52. Lung 11%
53. Lymph Node 6%
54. Lymph Node Metastasis 11%
55. Margin Quality 11%
56. Median Arcuate Ligament 11%
57. Minimally Invasive Distal Pancreatectomy 11%
58. Moving on 11%
59. Multidisciplinary Therapy 11%
60. Near-infrared Photoimmunotherapy (NIR-PIT) 11%
61. Neoadjuvant Chemoradiotherapy (nCRT) 11%
62. Neoadjuvant Therapy 11%
63. Older Men 9%
64. Oncological Outcomes 11%
65. Para-aortic Lymph Node Metastasis 11%
66. Perianal Lesion 8%
67. Postoperative Course 9%
68. Postoperative Follow-up 11%
69. Progressive Disease 5%
70. Propensity Score Analysis 11%
71. R0 Resection 12%
72. Radiation Therapy 11%
73. Rectal Carcinoma 11%
74. Rehepatectomy 11%
75. Resectable Pancreatic Cancer 11%
76. Resection 11%
77. Retrospective Analysis 11%
78. Robot-assisted Surgery 22%
79. Robotic Distal Gastrectomy 16%
80. Robotic Gastrectomy 11%
81. Robotic Rectal Surgery 11%
82. Robotic Surgery 12%
83. S-system 11%
84. Short-term Outcomes 11%
85. Single-center Retrospective Study 22%
86. Single-incision Laparoscopy 11%
87. Skip Metastasis 11%
88. Stable Disease 11%
89. Staging Laparoscopy 7%
90. Stomach 16%
91. Superior Mesenteric Artery 11%
92. Superior Rectal Artery 7%
93. Surgical Robot 12%
94. TME Quality 11%
95. Treatment Outcome 11%
96. Tumor 27%
97. Ulcerative Colitis 11%
98. Umbilical Port 11%
99. X-ray Study 7%
100. Young Males 7%